Harrow Inc(HROW) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:26 PM ET (Korea 9/12 05:26)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1 | Insider Own | 15.27% | Shs Outstand | 37.5M | Perf Week | -9.88% |
| Market Cap | 1.29B | Forward P/E | 15.54 | EPS next Y | 3220.32% | Insider Trans | 0.07% | Shs Float | 31.8M | Perf Month | -12.4% |
| Enterprise Value | 1.51B | PEG | - | EPS next Q | 0.2 | Inst Own | 57.7% | Short Float | 21.34% | Perf Quarter | -8.42% |
| Income | -0.04B | P/S | 4.69 | EPS this Y | 49.21% | Inst Trans | 2.04% | Short Ratio | 11.07 | Perf Half Y | -3.04% |
| Sales | 0.28B | P/B | 85.03 | EPS next 5Y | - | ROA | -9.77% | Short Interest | 6.78M | Perf YTD | -29.63% |
| Book/sh | 0.41 | P/C | 15.41 | EPS past 3/5Y | 35.17% -1.53% | ROE | -114.8% | 52W High | -37.14% ($54.85) | Perf Year | -12.6% |
| Cash/sh | 2.24 | P/FCF | 257.49 | Sales past 3/5Y | 45.39% 40.99% | ROIC | -11.82% | 52W Low | 20.81% ($28.54) | Perf 3Y | 107.59% |
| Dividend Est. | - | EV/EBITDA | 56 | EPS Y/Y TTM | -244.96% | Gross Margin | 73.28% | Volatility(W/M) | 2.81% 4.38% | Perf 5Y | 235.41% |
| Dividend TTM | - | EV/Sales | 5.48 | Sales Y/Y TTM | 21.05% | Oper. Margin | 2.07% | ATR (14) | 1.77 | Perf 10Y | 740.98% |
| Dividend Ex-Date | - | Quick Ratio | 2.08 | EPS Q/Q | -459.56% | Profit Margin | -13.51% | RSI (14) | 33.16 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.24 | Sales Q/Q | 10.85% | SMA20 | -11.15% ($38.81) | Beta | 0.17 | Target Price | $65 |
| Payout | - | Debt/Eq | 19.79 | Earnings | 2026/8/10 | SMA50 | -14.64% ($40.39) | Rel Volume | 1.61 | Prev Close | $36.58 |
| Employees | 373 | LT Debt/Eq | 19.72 | EPS/Sales Surpr. | -157.27% 0.44% | SMA200 | -16.4% ($41.24) | Avg Volume(3M) | 0.61M | Price | $34.48 |
| IPO | 2007/4/24 | Option/Short | Yes/Yes | Trades | 10468 | Volume | 982,961 | Change | -5.74% |
Company
HROW is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
👁️ Harpoon HROW is a US specialty pharmaceutical company focused on ophthalmology (eye care). Its core business is the development and commercialization of ophthalmic pharmaceuticals, and through ImprimisRx, its ophthalmic-focused compounding business, it supplies prescription eye drops and compounded products. The company is characterized by its concentration of resources in ophthalmology, a specific therapeutic area, allowing it to rapidly expand its portfolio of commercialized products.
Over the past 1 year, on the lower side
37% below its 1-year high.
HROW has weak earning power
Review management risk carefully before investing
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +49.2% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +107.6% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 57.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XPH 0.02%
PILL 0.01%
FDHY 0.01%
DWAS 0.01%
IHE 0.00%It ranks #4 in the industry
Based on market cap of $1B.
HROW $1B PER -
TAK $58B PER -
TEVA $43B PER 62.4
HLN $40B PER 18.9
FAQ
What kind of company is HROW?
HROW belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of HROW?
The market cap of HROW is approximately $1.3B, ranking 2,449 within its sector.
What is the 52-week high and low for HROW?
HROW has recorded a 52-week high of $54.85 and a low of $28.54.
